Autologous Hematopoietic Stem Cell Transplantation is flagged as a low confidence because it has an active early-phase oncology cell-therapy trial at M.D. Anderson Cancer Center, with a unlinked patent signal linked through public patent-search heuristics. Manual review is still required.
Target: CD19
Cell type: NK_CELL
Indications: CD19 Positive, Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma
Sponsor: M.D. Anderson Cancer Center
Institution: M.D. Anderson Cancer Center
Phase: Phase1
Status: Withdrawn
Trial count: 1
Active trials: 0
First posted: July 9, 2018
Last updated: January 29, 2020
IP signal: Unlinked
BD label: Low Confidence
Confidence: Low
Manual review required: Yes
Review the underlying ClinicalTrials.gov record and treat Treelip output as a prioritization layer, not a final diligence conclusion.
NCT IDs: NCT03579927